Advertisement

Annals of Surgical Oncology

, Volume 12, Issue 10, pp 765–777 | Cite as

Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Current Status and Future Directions

  • John H. StewartIV
  • Perry Shen
  • Edward A. Levine
Educational Review

Abstract

Natural history studies have shown that peritoneal carcinomatosis is uniformly fatal, with a median survival in the range of approximately 6 months. For more than a decade, a handful of centers have pursued aggressive intraperitoneal cytoreductive surgery combined with intraperitoneal hyperthermic chemotherapy as an alternative approach to this disease. Strict selection criteria, variation in intraperitoneal chemotherapy, and the vagaries of what represents “cytoreductive surgery” make many of our colleagues, particularly those in medical oncology, reticent to refer patients for such an aggressive therapy. This article establishes a conceptual framework for understanding the role of intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal surface malignancy. This procedure continues to make advancements in the oncological community despite formidable challenges. The advancement of centers of excellence and the initiation of further phase II trials will help to define the optimal treatment approach for peritoneal carcinomatosis.

Keywords

Peritoneal dissemination Carcinomatosis Intraperitoneal hyperthermic chemotherapy Mitomycin C Cytoreductive surgery. 

References

  1. 1.
    Blair SL, Chu DZ, Schwarz RE. Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer. Ann Surg Oncol 2001;8:632–7PubMedGoogle Scholar
  2. 2.
    Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002;89:1545–50CrossRefPubMedGoogle Scholar
  3. 3.
    Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001;67:999–1003. PubMedGoogle Scholar
  4. 4.
    Koga S. [Prophylactic and therapeutic continuous hyperthermic peritoneal perfusion for peritoneal metastases of gastric cancer]. Gan No Rinsho 1985;31:1103–5PubMedGoogle Scholar
  5. 5.
    Fizazi K, Doubre H, Le Chevalier T et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 2003;21:349–54CrossRefPubMedGoogle Scholar
  6. 6.
    Spratt JS, Adcock RA, Sherrill W, Travathen S. Hyperthermic peritoneal perfusion system in canines. Cancer Res 1980;40:253–5PubMedGoogle Scholar
  7. 7.
    Fujimoto S, Shrestha RD, Kokubun M et al. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg 1988;208:36–41PubMedGoogle Scholar
  8. 8.
    Meyers MA. Distribution of intra-abdominal malignant seeding: dependency on dynamics of flow of ascitic fluid. Am J Roentgenol Radium Ther Nucl Med 1973;119:198–206PubMedGoogle Scholar
  9. 9.
    Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev 2003;22:465–72CrossRefPubMedGoogle Scholar
  10. 10.
    Averbach AM, Jacquet P, Sugarbaker PH. Surgical technique and colorectal cancer: impaction on local recurrence and survival. Tumori 1995;81:65–71PubMedGoogle Scholar
  11. 11.
    Eggermont AM, Steller EP, Sugarbaker PH. Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. Surgery 1987;102:71–8PubMedGoogle Scholar
  12. 12.
    Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 1997;89:480–7Google Scholar
  13. 13.
    Dedrick RL. Interspecies scaling of regional drug delivery. J Pharm Sci 1986;75:1047–52Google Scholar
  14. 14.
    Flessner MF, Dedrick RL, Schultz JS. A distributed model of peritoneal-plasma transport: analysis of experimental data in the rat. Am J Physiol 1985;248:F413–F424PubMedGoogle Scholar
  15. 15.
    Kuzuya T, Yamauchi M, Ito A, Hasegawa M, Hasegawa T, Nabeshima T Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol 1994;46:685–9PubMedGoogle Scholar
  16. 16.
    Speyer JL, Collins JM, Dedrick RL, et al. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 1980;40:567–72PubMedGoogle Scholar
  17. 17.
    Israel VK, Jiang C, Muggia FM, et al. Intraperitoneal 5-fluoro-2′-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Cancer Chemother Pharmacol 1995;37:32–8PubMedGoogle Scholar
  18. 18.
    Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Greene R, Jenkins J, Myers CE et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 1982;42:4265–9PubMedGoogle Scholar
  19. 19.
    Bartlett DL, Buell JF, Libutti SK et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 1998;83:1251–61CrossRefPubMedGoogle Scholar
  20. 20.
    Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992;118:547–50CrossRefPubMedGoogle Scholar
  21. 21.
    Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 1998;16:2620–4PubMedGoogle Scholar
  22. 22.
    Dikomey E, Franzke J. Effect of heat on induction and repair of DNA strand breaks in X-irradiated CHO cells. Int J Radiat Biol 1992;61:221–33PubMedGoogle Scholar
  23. 23.
    Roti Roti JL, Kampinga HH, Malyapa RS, Wright WD, vanderwaal RP, Xu M, et al. Nuclear matrix as a target for hyperthermic killing of cancer cells. Cell Stress Chaperones 1998;3:245–55CrossRefPubMedGoogle Scholar
  24. 24.
    Glehen O, Osinsky D, Cotte E et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003;10:863–9Google Scholar
  25. 25.
    Elias D, Bonnay M, Puizillou JM et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 2002;13:267–72CrossRefPubMedGoogle Scholar
  26. 26.
    Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 1980;40:1165–8PubMedGoogle Scholar
  27. 27.
    El Kareh AW, Secomb TW. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia 2004;6:117–27PubMedGoogle Scholar
  28. 28.
    Liakakos T, Thomakos N, Fine PM, Dervenis C, Young RL. Peritoneal adhesions: etiology, pathophysiology, and clinical significance. Recent advances in prevention and management. Dig Surg 2001;18:260–73CrossRefPubMedGoogle Scholar
  29. 29.
    Raftery AT. Regeneration of peritoneum: a fibrinolytic study. J Anat 1979;129:659–64PubMedGoogle Scholar
  30. 30.
    Markman M, Cleary S, Howell SB, Lucas WE. Complications of extensive adhesion formation after intraperitoneal chemotherapy. Surg Gynecol Obstet 1986;162:445–8Google Scholar
  31. 31.
    Topuz E, Saip P, Aydiner A, Salihoglu Y, Aydin Y, Topuzlu C et al. Catheter complications associated with intraperitoneal chemotherapy. Eur J Gynaecol Oncol 1998;19:275–9PubMedGoogle Scholar
  32. 32.
    Kodera Y, et al. Peritoneal washing cytology: prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection. J Surg Oncol 1999;72:60–4CrossRefPubMedGoogle Scholar
  33. 33.
    Basha G, Ghirardi M, Geboes K, Yap SH, Penninckx F. Limitations of peritoneal lavage with antiseptics in prevention of recurrent colorectal cancer caused by tumor-cell seeding: experimental study in rats. Dis Colon Rectum 2000;43:1713–8PubMedGoogle Scholar
  34. 34.
    Sweitzer KL, Nathanson SD, Nelson LT, Zachary C. Irrigation does not dislodge or destroy tumor cells adherent to the tumor bed. J Surg Oncol 1993;53:184–90PubMedGoogle Scholar
  35. 35.
    Dawson LE, Russell AH, Tong D, Wisbeck WM. Adenocarcinoma of the sigmoid colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. J Surg Oncol 1983;22:95–9PubMedGoogle Scholar
  36. 36.
    Russell AH, Tong D, Dawson LE, et al. Adenocarcinoma of the retroperitoneal ascending and descending colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. Int J Radiat Oncol Biol Phys 1983;9:361–5PubMedGoogle Scholar
  37. 37.
    Deraco M, Raspagliesi F, Kusamura S. Management of peritoneal surface component of ovarian cancer. Surg Oncol Clin North Am 2003;12:561–83Google Scholar
  38. 38.
    Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology 2000;58:96–107CrossRefPubMedGoogle Scholar
  39. 39.
    Moertel CG. Peritoneal mesothelioma. Gastroenterology 1972;63:346–50PubMedGoogle Scholar
  40. 40.
    Chan PS, Balfour TW, Bourke JB, Smith PG. Peritoneal nesothelioma. Br J Surg 1975;62:576–80PubMedGoogle Scholar
  41. 41.
    McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD et al. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 2001;27:65–73CrossRefPubMedGoogle Scholar
  42. 42.
    Brenner J, Sordillo PP, Magill GB, Golbey RB. Malignant peritoneal mesothelioma: review of 25 patients. Am J Gastroenterol 1981;75:311–3PubMedGoogle Scholar
  43. 43.
    Sadeghi B, Arvieux C, Glehen O et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358–63CrossRefPubMedGoogle Scholar
  44. 44.
    McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1–6CrossRefPubMedGoogle Scholar
  45. 45.
    Antman KH, Osteen RT, Klegar KL, Amato DA, Pomfret EA, Lanson DA, Corson JM et al. Early peritoneal mesothelioma: a treatable malignancy. Lancet 1985;2:977–81CrossRefPubMedGoogle Scholar
  46. 46.
    Shen P, Levine EA, Hall J et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003;138:26–33PubMedGoogle Scholar
  47. 47.
    Loggie BW, Perini M, Fleming RA, Russell GB, Geisinger K. Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy. Am Surg 1997;63:137–43Google Scholar
  48. 48.
    de Bree E, et al. Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol 2004;86:64–73CrossRefPubMedGoogle Scholar
  49. 49.
    Kubik-Huch RA, et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000;10:761–7Google Scholar
  50. 50.
    Low RN, et al. Peritoneal tumor: MR imaging with dilute oral barium and intravenous gadolinium-containing contrast agents compared with unenhanced MR imaging and CT. Radiology 1997;204:513–20Google Scholar
  51. 51.
    Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 2001;82:17–21CrossRefPubMedGoogle Scholar
  52. 52.
    Iwamoto A, et al. [Intraoperative chemotherapy with intraperitoneal activated carbon particles adsorbing mitomycin C against peritoneal dissemination of gastric cancer]. Gan To Kagaku Ryoho 1989;16:2748–51PubMedGoogle Scholar
  53. 53.
    Fujimoto S, et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 1997;79:884–91CrossRefPubMedGoogle Scholar
  54. 54.
    Ouchi K, et al. Therapeutic significance of palliative operations for gastric cancer for survival and quality of life. J Surg Oncol 1998;69:41–4CrossRefPubMedGoogle Scholar
  55. 55.
    Hagiwara A, et al. Extensive gastrectomy and carbon-adsorbed mitomycin C for gastric cancer with peritoneal metastases. Case reports of survivors and their implications. Hepatogastroenterology 1999;46:1673–7Google Scholar
  56. 56.
    Ronnett BM, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol 1995;19:1390–408PubMedGoogle Scholar
  57. 57.
    Gilly FN, et al. Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 1994;41:124–9Google Scholar
  58. 58.
    Beaujard AC, et al. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 2000;88:2512–9CrossRefPubMedGoogle Scholar
  59. 59.
    Rey Y, Porcheron J, Talabard JN, Szafnicki K, Balique JG. [Peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemohyperthermia]. Ann Chir 2000;125:631–42CrossRefPubMedGoogle Scholar
  60. 60.
    Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727–31CrossRefPubMedGoogle Scholar
  61. 61.
    Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2004;14:35–41CrossRefPubMedGoogle Scholar
  62. 62.
    Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000;87:1587–93CrossRefPubMedGoogle Scholar
  63. 63.
    Tentes AA, et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol 2003;29:69–73CrossRefPubMedGoogle Scholar
  64. 64.
    Berthet B, Sugarbaker TA, Chang D, Sugarbaker PH. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer 1999;35:413–9CrossRefPubMedGoogle Scholar
  65. 65.
    Sebbag G, Sugarbaker PH. Peritoneal mesothelioma proposal for a staging system. Eur J Surg Oncol 2001;27:223–4CrossRefPubMedGoogle Scholar
  66. 66.
    Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999;43(Suppl):S15–25CrossRefPubMedGoogle Scholar
  67. 67.
    Leunig M, et al. Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res 1992;52:487–90PubMedGoogle Scholar
  68. 68.
    Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988;48:7022–32PubMedGoogle Scholar
  69. 69.
    Culliford AT, et al. Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol 2001;8:787–95PubMedGoogle Scholar
  70. 70.
    Marcus EA, et al. Prognostic factors affecting survival in patients with colorectal carcinomatosis. Cancer Invest 1999;17:249–52PubMedGoogle Scholar
  71. 71.
    Glehen O, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 2003;21:799–806CrossRefPubMedGoogle Scholar
  72. 72.
    Yonemura Y, et al. A new surgical approach (peritonectomy) for the treatment of peritoneal dissemination. Hepatogastroenterology 1999;46:601–9PubMedGoogle Scholar
  73. 73.
    Portilla AG, Sugarbaker PH, Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg 1999;23:23–9CrossRefPubMedGoogle Scholar
  74. 74.
    Sugarbaker PH, et al. Pseudomyxoma peritonei syndrome. Adv Surg 1996;30:233–80PubMedGoogle Scholar
  75. 75.
    Stephens AD, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999;6:790–6CrossRefPubMedGoogle Scholar
  76. 76.
    Ahmad SA, et al. Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion. Ann Surg Oncol 2004;11:387–92CrossRefPubMedGoogle Scholar
  77. 77.
    McQuellon RP, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003;10:155–62Google Scholar
  78. 78.
    Alexander HR, Mavroukakis SM, Libutti SK, et al. Impact of tumor resection and intraperitoneal chemotherapy on health related quality of life in patients with peritoneal surface malignancies. In: Proceedings of the 57th Annual Society of Surgical Oncology Cancer Symposium. March 18, 2004. Philadelphia: Lippincott, Williams, and Wilkens, 2004Google Scholar
  79. 79.
    Glehen O, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004;139:20–6CrossRefPubMedGoogle Scholar
  80. 80.
    Witkamp AJ, et al. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 2001;88:458–63CrossRefPubMedGoogle Scholar
  81. 81.
    Pestieau SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. Dis Colon Rectum 2000;43:1341–6Google Scholar
  82. 82.
    Glehen O, et al. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 2004;91:747–54CrossRefPubMedGoogle Scholar
  83. 83.
    Verwaal VJ, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737–43CrossRefPubMedGoogle Scholar
  84. 84.
    Glehen O, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284–92CrossRefPubMedGoogle Scholar
  85. 85.
    Hall JJ, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 2004;8:454–63CrossRefPubMedGoogle Scholar
  86. 86.
    Yonemura Y, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterology 2001;48:1776–82PubMedGoogle Scholar
  87. 87.
    Yonemura Y, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 1996;119:437–44PubMedGoogle Scholar
  88. 88.
    Deraco M, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 2001;87:120–6PubMedGoogle Scholar
  89. 89.
    Elias D, et al. [Pseudomyxoma peritonei treated with complete resection and immediate intraperitoneal chemotherapy]. Gastroenterol Clin Biol 2003;27:407–12PubMedGoogle Scholar
  90. 90.
    Deraco M, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004;11:393–8CrossRefPubMedGoogle Scholar
  91. 91.
    Stewart JH, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol 2004;12(Suppl):S32 (abstr 79)Google Scholar
  92. 92.
    Costamagna D, Scuderi S, Vaira M, Barone R, De Simone M. [Treatment of peritoneal mesothelioma using cytoreduction and intraperitoneal hyperthermic chemotherapy]. Tumori 2003;89:40–2PubMedGoogle Scholar
  93. 93.
    Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin North Am 2003;12:605–21, xiGoogle Scholar
  94. 94.
    Park BJ, et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999;6:582–90CrossRefPubMedGoogle Scholar
  95. 95.
    Deraco M, et al. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol 2003;83:147–53CrossRefPubMedGoogle Scholar
  96. 96.
    Feldman AL, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003;21:4560–7CrossRefPubMedGoogle Scholar
  97. 97.
    Kinsella TJ, Sindelar WF, Lack E, Glatstein E, Rosenberg SA. Preliminary results of a randomized study of adjuvant radiation therapy in resectable adult retroperitoneal soft tissue sarcomas. J Clin Oncol 1988;6:18–25PubMedGoogle Scholar
  98. 98.
    Karakousis CP, Gerstenbluth R, Kontzoglou K, Driscoll DL. Retroperitoneal sarcomas and their management. Arch Surg 1995;130:1104–9PubMedGoogle Scholar
  99. 99.
    Pirayesh A, et al. The management of retroperitoneal soft tissue sarcoma: a single institution experience with a review of the literature. Eur J Surg Oncol 2001;27:491–7CrossRefPubMedGoogle Scholar
  100. 100.
    Rossi CR, et al. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients. Cancer 2004;100:1943–50CrossRefPubMedGoogle Scholar
  101. 101.
    Levine EA. Problems of success and problems of failure: recurrent disease after cytoreductive surgery and intraperitoneal chemoperfusion. Ann Surg Oncol 2004;11:351–3CrossRefPubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2005

Authors and Affiliations

  • John H. StewartIV
    • 1
  • Perry Shen
    • 1
  • Edward A. Levine
    • 1
  1. 1.Surgical Oncology Service, Department of General SurgeryWake Forest University School of MedicineWinston-SalemNorth Carolina

Personalised recommendations